A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.
Lymphoma
DRUG: liposomal doxorubicin
the incidence of interstitial pneumonia, interstitial pneumonia is defined as positive CT scan with or without positive respiratory symptoms, up to one month after completion of study treatment
overall response rate, percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria, 21 days after completion of study treatment|adverse events, number of participants with treatment-related adverse events mainly include liposomal related AEs, eg cardiotoxicity and the incidence of hand-foot syndrome, up to 30 days after completion of study treatment
This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.